首页> 外文期刊>Virus Research: An International Journal of Molecular and Cellular Virology >Engineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins.
【24h】

Engineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins.

机译:用CD4受体和融合蛋白假型化的工程化慢病毒载体可以靶向表达HIV-1包膜蛋白的细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

Lentiviral vectors (LVs) derived from human immunodeficiency virus type 1 (HIV-1) are promising vehicles for gene delivery because they not only efficiently transduce both dividing and non-dividing cells, but also maintain long-term transgene expression. Development of an LV system capable of transducing cells in a cell type-specific manner can be beneficial for certain applications that rely on targeted gene delivery. Previously it was shown that an inverse fusion strategy that incorporated an HIV-1 receptor (CD4) and its co-receptor (CXCR4 or CCR5) onto vector surfaces could confer to LVs the ability to selectively deliver genes to HIV-1 envelope-expressing cells. To build upon this work, we aim to improve its relatively low transduction efficiency and circumvent its inability to target multiple tropisms of HIV-1 by a single vector. We investigated a method to create LVs co-enveloped with the HIV-1 cellular receptor CD4 and a fusogenic protein derived from the Sindbis virus glycoprotein and tested its efficiency to selectively deliver genes into cells expressing HIV-1 envelope proteins. The engineered LV system yields a higher level of transduction efficiency and a broader tropism towards cells displaying the HIV-1 envelope protein (Env) than the previously developed system. Furthermore, we demonstrated in vitro that this engineered LV can preferentially deliver suicide gene therapy to HIV-1 envelope-expressing cells. We conclude that it is potentially feasible to target LVs towards HIV-1-infected cells by functional co-incorporation of the CD4 and fusogenic proteins, and provide preliminary evidence for further investigation on a potential alternative treatment for eradicating HIV-1-infected cells that produce drug-resistant viruses after highly active antiretroviral therapy (HAART).
机译:源自1型人类免疫缺陷病毒(HIV-1)的慢病毒载体(LVs)是有前途的基因传递载体,因为它们不仅有效地转导分裂细胞和非分裂细胞,而且还能长期保持转基因表达。能够以细胞类型特异性方式转导细胞的LV系统的开发对于某些依赖于靶向基因递送的应用可能是有益的。以前的研究表明,将HIV-1受体(CD4)及其共受体(CXCR4或CCR5)掺入载体表面的反向融合策略可以赋予LVs选择性地将基因递送至表达HIV-1膜的细胞的能力。在此工作的基础上,我们旨在提高其相对较低的转导效率,并避免其无法通过单一载体靶向HIV-1的多种向性。我们研究了一种创建与HIV-1细胞受体CD4和衍生自Sindbis病毒糖蛋白的融合蛋白共包裹的LV的方法,并测试了其选择性地将基因传递到表达HIV-1包膜蛋白的细胞中的效率。经过改造的LV系统与以前开发的系统相比,对显示HIV-1包膜蛋白(Env)的细胞具有更高的转导效率和更广泛的向性。此外,我们在体外证明,该工程改造的LV可以优先向表达HIV-1膜的细胞提供自杀基因治疗。我们得出结论,通过功能性共掺入CD4和融合蛋白,将LVs靶向HIV-1感染的细胞是可行的,并为进一步研究根除可能感染HIV-1的细胞的替代疗法提供了初步证据。经过高度有效的抗逆转录病毒疗法(HAART)可以产生抗药性病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号